KMTV Omaha - Interview with Omaha native, Dr. Julie Brahmer

(4:16)

Dr. Brahmer Explains PD-1 and PD-L1

(1:43)

Dr. Brahmer on Distinguishing Between Immunotherapy Response and Cancer Growth

(1:16)

Dr. Brahmer on the Role of Immunotherapy in Metastatic NSCLC

(1:31)

Dr. Brahmer Discusses the Management of Adverse Events From Immunotherapy

(1:30)

Dr. Bror Saxberg - TEDxSF - Demystifying the Human Mind

(19:25)

Replay of the Live Conversation with Dr. Barbara Natterson Horowitz

(1:5:46)

Brain Tumor Awareness Month

(2:58)

How is Immunotherapy Used to Fight Cancer? | Dana-Farber Cancer Institute | Science Illustrated

(2:44)

PD-1, PD-L1 role in immune system inhibition

(6:8)

Immunotherapy for Lung Cancer: What Patients Need to Know, with Julie Brahmer

(1:52)

April 9, 2024 - Beshay Zordosky, MSc, PhD

(59:9)

The basic biology of PD-1/PD-L1

(26:40)

Gemeinderatswahlen in NÖ: ÖVP erleichtert, FPÖ holt auf l exxpress live am 27. Jänner 2025

(1:2:48)

BRAF Targeted Therapy - Melanoma Education Symposium, Peter Boasberg MD

(22:44)

Dr. Brahmer on the Benefit of Immunotherapy in Metastatic NSCLC

(1:32)

Dr. Julie R. Brahmer on Immunotherapy Development in Lung Cancer

(58)

Join Dr. Brahmer at the 20th Annual Winter Lung Cancer Conference

(1:31)

Copy of Dr. Brahmer on the Role of Immunotherapy in Metastatic NSCLC

(31)

Dr. Brahmer on 5-Year Follow-Up Data for Nivolumab in NSCLC

(1:18)

Dr. Brahmer Discusses the Future of Antibodies for Lung Cancer

(1:56)

Dr. Julie Brahmer named Meyerhoff Professor in Thoracic Oncology

(29:54)

Copy of Dr. Brahmer on Immunotherapy in Stage IV NSCLC

(19)

Dr. Brahmer Discusses Frontline Single-Agent Pembrolizumab in Lung Cancer

(1:48)

Dr. Brahmer Discusses Response to Immunotherapy

(1:25)

Dr. Brahmer on Immunotherapy Beyond PD-1/L1 in NSCLC

(1:15)

Dr. Brahmer Discusses the Outlook for Immunotherapies

(58)

Dr. Brahmer Discusses Tumor Vaccines for Lung Cancer

(2:3)

Dr. Brahmer on Biomarkers for Immune Response in NSCLC

(1:23)